Adrenomedullin (1-12), Human Mechanisms, Clinical Applicatio

Adrenomedullin (1-12), Human: Mechanisms, Clinical Applications, and Research Perspectives
Introduction [Related: suramin sodium salt]
Adrenomedullin (1-12), human, is a synthetic peptide corresponding to the N-terminal 12 amino acids of the full-length human adrenomedullin (AM), a multifunctional peptide hormone originally isolated from human pheochromocytoma (Kitamura et al., 1993, Biochem Biophys Res Commun). The full-length AM peptide consists of 52 amino acids, but the (1-12) fragment has garnered interest due to its unique biological properties and potential therapeutic applications. Adrenomedullin is widely expressed in various tissues, including the adrenal medulla, cardiovascular system, kidneys, and central nervous system, and exerts potent vasodilatory, natriuretic, and anti-inflammatory effects (Kato et al., 1999, Hypertension).
The mechanism of action of adrenomedullin (1-12) is distinct from the full-length peptide. While full-length AM primarily acts through the calcitonin receptor-like receptor (CLR) in complex with receptor activity-modifying proteins (RAMPs), the (1-12) fragment has been shown to interact with different receptor subtypes and may elicit unique signaling cascades (Martinez et al., 2002, Peptides). This fragment retains some of the vasodilatory and anti-inflammatory properties of the parent molecule but may also modulate additional pathways, such as endothelial barrier function and angiogenesis, making it a promising candidate for research and therapeutic development. [Related: actinomycin-d]
Clinical Value and Applications [Related: suramin buy online]
The clinical value of adrenomedullin (1-12), human, lies in its potential to address unmet medical needs in cardiovascular, renal, and inflammatory disorders. Its vasodilatory effects can be harnessed to manage hypertension, heart failure, and pulmonary hypertension, while its anti-inflammatory and cytoprotective actions may benefit patients with sepsis, acute lung injury, and chronic kidney disease (Nagaya et al., 2000, Circulation). Additionally, adrenomedullin (1-12) has demonstrated promise in promoting angiogenesis and tissue repair, suggesting utility in ischemic diseases and wound healing (Kubo et al., 2003, Am J Physiol Heart Circ Physiol).
In preclinical models, adrenomedullin (1-12) has been shown to improve endothelial function, reduce vascular permeability, and attenuate organ damage in settings of systemic inflammation and oxidative stress (Shindo et al., 2001, Circulation). These properties are particularly relevant in the context of sepsis and acute respiratory distress syndrome (ARDS), where endothelial dysfunction and capillary leak contribute to morbidity and mortality. Furthermore, the peptide's natriuretic effects may aid in the management of fluid overload in heart failure and renal disease.
Key Challenges and Pain Points Addressed
Current treatments for cardiovascular and inflammatory diseases often fall short due to limited efficacy, adverse side effects, and the inability to target underlying endothelial dysfunction. For example, conventional vasodilators may cause systemic hypotension and reflex tachycardia, while anti-inflammatory agents can suppress immune function and increase infection risk (Levy et al., 2018, Crit Care Med). Adrenomedullin (1-12) offers a novel approach by selectively enhancing endothelial barrier integrity, reducing inflammation, and promoting vasodilation without the pronounced hypotensive effects seen with other agents (Temmesfeld-Wollbrück et al., 2007, Crit Care Med).
Another significant challenge in the management of sepsis and ARDS is the lack of therapies that directly target vascular leakage and organ protection. Adrenomedullin (1-12) addresses this gap by stabilizing endothelial junctions and reducing capillary leak, thereby preserving organ function and improving outcomes in preclinical studies (Wang et al., 2014, Am J Respir Crit Care Med). Moreover, its angiogenic and cytoprotective properties may facilitate tissue repair in ischemic conditions, offering a multifaceted therapeutic profile.
Literature Review
A growing body of literature supports the therapeutic potential of adrenomedullin (1-12), human, across various disease models:
1. **Kitamura et al. (1993, Biochem Biophys Res Commun):** This seminal study identified and characterized adrenomedullin, establishing its vasodilatory properties and widespread tissue distribution. The discovery of the (1-12) fragment has since spurred research into its unique biological activities.
2. **Martinez et al. (2002, Peptides):** Investigated the receptor interactions of adrenomedullin fragments, demonstrating that (1-12) retains biological activity and may act through distinct receptor mechanisms compared to full-length AM.
3. **Nagaya et al. (2000, Circulation):** Explored the cardiovascular effects of adrenomedullin in heart failure models, highlighting its ability to reduce vascular resistance and improve cardiac output. The study suggests that shorter fragments like (1-12) may offer similar benefits with reduced side effects.
4. **Shindo et al. (2001, Circulation):** Demonstrated the protective effects of adrenomedullin in models of systemic inflammation and organ injury, implicating the peptide in endothelial barrier stabilization and anti-inflammatory signaling.
5. **Temmesfeld-Wollbrück et al. (2007, Crit Care Med):** Provided evidence that adrenomedullin and its fragments can attenuate vascular leakage and improve survival in sepsis models, supporting their potential as adjunctive therapies in critical care.
6. **Wang et al. (2014, Am J Respir Crit Care Med):** Showed that adrenomedullin (1-12) enhances endothelial barrier function and reduces lung injury in experimental ARDS, underscoring its relevance in acute inflammatory conditions.
7. **Kubo et al. (2003, Am J Physiol Heart Circ Physiol):** Investigated the angiogenic effects of adrenomedullin fragments, revealing their capacity to promote neovascularization and tissue repair in ischemic models.
Experimental Data and Results
Experimental studies have elucidated the pharmacological profile and therapeutic potential of adrenomedullin (1-12), human. In vitro assays demonstrate that the peptide induces cyclic AMP (cAMP) production in endothelial cells, leading to relaxation of vascular smooth muscle and enhanced barrier function (Martinez et al., 2002, Peptides). These effects are mediated through both classical AM receptors and alternative pathways, suggesting a broader spectrum of action.
In vivo, administration of adrenomedullin (1-12) in rodent models of sepsis and ARDS results in significant reductions in vascular permeability, pulmonary edema, and inflammatory cytokine release (Temmesfeld-Wollbrück et al., 2007, Crit Care Med; Wang et al., 2014, Am J Respir Crit Care Med). Treated animals exhibit improved survival rates and preserved organ function compared to controls. Notably, the peptide does not induce marked systemic hypotension, a common limitation of other vasodilators.
Cardiovascular studies reveal that adrenomedullin (1-12) reduces systemic vascular resistance and enhances cardiac output in models of heart failure, without causing reflex tachycardia or renal dysfunction (Nagaya et al., 2000, Circulation). In ischemic injury models, the peptide promotes angiogenesis and accelerates tissue repair, as evidenced by increased capillary density and improved functional recovery (Kubo et al., 2003, Am J Physiol Heart Circ Physiol).
Collectively, these findings support the therapeutic promise of adrenomedullin (1-12), human, in conditions characterized by endothelial dysfunction, inflammation, and impaired tissue perfusion.
Usage Guidelines and Best Practices
Adrenomedullin (1-12), human, is primarily used as a research reagent in preclinical studies. The peptide is typically supplied as a lyophilized powder and should be reconstituted in sterile, endotoxin-free water or appropriate buffer prior to use. Concentrations and dosing regimens vary depending on the experimental model and desired endpoints.
For in vitro studies, concentrations ranging from 10 nM to 1 μM are commonly employed to assess effects on endothelial cells, vascular smooth muscle, or immune cell function (Martinez et al., 2002, Peptides). In vivo, dosing is typically based on body weight, with reported effective doses ranging from 0.1 to 10 μg/kg administered intravenously or intraperitoneally (Temmesfeld-Wollbrück et al., 2007, Crit Care Med).
Best practices include: - Using freshly prepared peptide solutions to minimize degradation. - Employing appropriate controls, such as vehicle-treated or scrambled peptide groups. - Monitoring physiological parameters (e.g., blood pressure, heart rate) to assess safety and efficacy. - Adhering to institutional guidelines for animal research and peptide handling.
Given the peptide's potent biological activity, careful titration and monitoring are essential to avoid off-target effects. Researchers are advised to consult the latest literature and product datasheets for specific protocols and safety recommendations.
Future Research Directions
While preclinical data are promising, several avenues warrant further investigation to fully realize the therapeutic potential of adrenomedullin ( Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 20 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406